CD8A and neoplasm: While clinical trial outcomes of DC-based vaccines have proved disappointing, recent research has underscored the pivotal role of DC-mediated cross-priming in eliciting anti-tumor CD8 T cell immunity and modulating the anti-tumor effects of immunotherapies.